Genome-editing technology has broad potential for treating cancers
the ONA take:
Researchers from the Walter and Eliza Hall Institute, in Melbourne, Australia, have developed a new genome editing technology that can target and kill blood cancer cells with high accuracy.
Using the technology, called CRISPR, the researchers were able to kill human lymphoma cells by locating and deleting an essential gene for cancer cell survival.
The technology can directly target any gene in a person’s genome, thereby overcoming many problems commonly encountered in drug development.
The system works by efficiently locating and targeting a particular gene. It can introduce mutations that make the genome nonfunctional, or introduce changes that make mutated genes function normally again.
The researchers report that the technology has a wide range of potential in terms of drug development for treating genetic diseases such as cancer.
Researchers have developed a new genome editing technology that can target and kill blood cancer cells with high accuracy.
- Acupuncture Improves Postoperative Symptoms in Women Undergoing Surgery for Breast Cancer
- Prehabilitation Program Improves Preoperative Fitness in Patients With Colorectal Cancer
- Combination of Gemcitabine and New CHK1 Inhibitor Is Effective in Soft Tissue Sarcomas
- Alcohol Consumption, Particularly White Wine, Associated With Increased Risk of Melanoma
- In HER2+ Breast Cancer, Higher TIL Levels Associated With Improved OS
- Exercise is as Effective in Treating Metastatic Prostate Cancer as Medication
- Walnut Consumption Changes Gut Microbiome, Decreases Growth of Colon Cancer in Mice
- Vaccine Enters Phase I Study for Safety and Effectiveness in Multiple Myeloma
- Timing Chemotherapy Administration to Circadian Rhythm Improves Drug Effectiveness
- New Therapy Blocks Breast Cancer Cells From Entering and Hiding in Bone Marrow to Form Latent Metastases
- Dual HER2 Blockade With an AI Effective in Advanced Breast Cancer
- Loperamide Regimen May Reduce Diarrhea in Neratinib-treated Patients
- PAM50 HER2-E Subtype Predicts pCR Following Lapatinib, Trastuzumab
- Arsenic Pretreatment May Protect Normal Tissue During Chemo in Breast Cancer
- Netupitant/Palonosetron Efficacious for Prevention of N/V in Patients Receiving MEC or HEC
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|